Literature DB >> 17689973

Left ventricular mass: impact on left ventricular contractile function and its reversibility in patients undergoing aortic valve replacement.

Kazuhiro Taniguchi1, Toshiki Takahashi, Koichi Toda, Hajime Matsue, Yasuhiro Shudo, Hideo Shintani, Masataka Mitsuno, Yoshiki Sawa.   

Abstract

BACKGROUND: We examined the relationships of left ventricular (LV) contractile state with LV geometry and hypertrophy in patients with aortic valve disease, and investigated the reversibility of LV hypertrophy and contractility following aortic valve replacement.
METHODS: Preoperative data from quantitative cineangiography and pressure measurements in 132 patients with chronic aortic valve disease, of whom 82 aortic regurgitation (AR), 41 aortic stenosis (AS), and 9 had mixed stenosis and regurgitation (AS-AR), were reviewed. Late after surgery, 59 of the patients (39 with AR, 20 with AS) were studied to elucidate the postoperative reversibility of LV performance and regression of LV hypertrophy.
RESULTS: Preoperatively, multiple comparison tests found significant changes in the variables of LV volumes and dimensions in relation to LV contractile state. In stepwise regression analysis, the LV mass index was initially incorporated into a multivariate regression model as an important correlate of LV contractile state. LV geometric variables showed either no or a poor correlation with contractile state. Following aortic valve replacement, improvement of LV contractile dysfunction and regression of LV hypertrophy were limited in many of the patients who had severe preoperative hypertrophy (LV mass index 200% of normal or greater). Further, a close association between LV hypertrophy and LV contractility persisted postoperatively.
CONCLUSION: Our results suggest that the development of LV hypertrophy in terms of an increase in LV mass index, in contrast to changes in geometric patterns, is significantly associated with deterioration in contractile function. LV hypertrophy may become irreversible and pathological at equivalent degrees of hypertrophy (LV mass index >/=200% of normal), regardless of the type of aortic valve lesion.

Entities:  

Mesh:

Year:  2007        PMID: 17689973     DOI: 10.1016/j.ejcts.2007.07.003

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

Review 1.  Contemporary reviews by surgeon: timing of operation for chronic aortic regurgitation.

Authors:  Kazuhiro Taniguchi; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-09-26

2.  The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis.

Authors:  Brian R Lindman; Suzanne V Arnold; José A Madrazo; Alan Zajarias; Stephanie N Johnson; Julio E Pérez; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2011-02-25       Impact factor: 8.790

3.  Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile.

Authors:  William E Stansfield; Peter C Charles; Ru-hang Tang; Mauricio Rojas; Rajendra Bhati; Nancy C Moss; Cam Patterson; Craig H Selzman
Journal:  J Thorac Cardiovasc Surg       Date:  2009-01       Impact factor: 5.209

4.  Speckle tracking echocardiography derived 2-dimensional myocardial strain predicts left ventricular function and mass regression in aortic stenosis patients undergoing aortic valve replacement.

Authors:  Adam Staron; Manish Bansal; Piyush Kalakoti; Ayumi Nakabo; Zbigniew Gasior; Piotr Pysz; Krystian Wita; Marek Jasinski; Partho P Sengupta
Journal:  Int J Cardiovasc Imaging       Date:  2012-11-30       Impact factor: 2.357

5.  Mechanical unloading activates FoxO3 to trigger Bnip3-dependent cardiomyocyte atrophy.

Authors:  Dian J Cao; Nan Jiang; Andrew Blagg; Janet L Johnstone; Raj Gondalia; Misook Oh; Xiang Luo; Kai-Chun Yang; John M Shelton; Beverly A Rothermel; Thomas G Gillette; Gerald W Dorn; Joseph A Hill
Journal:  J Am Heart Assoc       Date:  2013-04-08       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.